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New staging system for COPD 1547provide and prognostic value. We finally selected three: FEV1 (including arterial
blood gas measurements when FEV1 falls below 35% predicted), Medical Research
Council dyspnea scale and body mass index (BMI). Each measure correlates
independently with prognosis in COPD, is supported by a significant body of
literature and serves as a surrogate for other potentially important variables. We
then used principal components analysis (PCA) to determine the degree of
association between 30 of the potential variables measured in 813 stable COPD
patients.
Using PCA, six groups of measurements defined independent categories of patient
information: pulmonary function (including FEV1), symptoms of cough and sputum,
dyspnea, health status, bronchodilator reversibility and BMI. These include the three
principal variables selected for the staging system. Although the staging boundaries
were based on existing literature, they have proven useful in predicting survival. We
conclude that a multidimensional grading system is useful to assess the impact of
COPD.
& 2005 Published by Elsevier Ltd.Introduction
Chronic obstructive pulmonary disease (COPD) is
characterized by airflow limitation due to parench-
ymal destruction and airways inflammation. It is a
chronic disorder and a major cause of morbidity
and mortality.1 Indeed, COPD is the fourth leading
cause of death in the USA, where the mortality rate
of patients with the disease is still rising.2
Current management guidelines suggest that the
severity of COPD be assessed by a single physiolo-
gical measurement, the forced expiratory volume
in 1 s (FEV1).
3–5 However, COPD is associated with a
range of other impairments and clinical manifesta-
tions that are not closely related to the severity of
airflow limitation, such as a reduction in exercise
capacity,6 pulmonary hypertension7 and peripheral
muscle weakness.8 Post-bronchodilator FEV1 is
accepted as a good correlate of mortality in
COPD9,10 but the risk of dying from the disease
only rises substantially when the FEV1 is not the
only determinant of mortality in this popula-
tion10–13 and a number of other risk factors have
now been identified. These include the presence in
clinically stable patients of persistent hypoxemia or
hypercapnia,14 the timed walking distance after
completing pulmonary rehabilitation15 and a low
body mass index (BMI).14,16 Although the FEV1 is of
great value in defining COPD, it is clearly not the
only determinant of either the subsequent survival,
symptom intensity of the onset of complications.
Inevitably, this must restrict the applicability of any
classification or staging system based solely on this
variable. A recent publication documents the value
of a multidimensional index that included BMI (B),
degree of airflow obstruction (O), dyspnea (D) and
exercise performance (E) or BODE index, to predict
mortality.17This paper describes a different approach aimed
at developing a staging system which should be
both relatively easy to apply and suitable for
prospective testing.Methods
To develop our staging system, a two-step process
was adopted.(1) Identification of candidate variables: A panel of
expert clinicians identified variables that were
potentially useful, independent of each other
and with some evidence of a relationship with
one or more COPD outcomes. Subsequently,
each variable was assessed for the ease with
which it could be measured in a standardized
way in clinical practice.(2) The variables identified in step 1 that were the
most suitable for inclusion in the staging system
were subjected to statistical testing using a
COPD patient database, to confirm that they did
indeed describe different aspects of the disease.Candidate variables
A list of measurable variables was compiled, initially
without regard to the current practicality of their
measurement. These were separated into variables
that reflect (directly or indirectly) altered pulmonary
structure and function, or can be considered to be
extrapulmonary predictors of disease severity or
consequences of COPD itself (Table 1). In each case,
there is evidence from one or more studies to
support the relationship between the candidate
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Table 1 Measurable variables considered for inclusion in a COPD staging system.
Extrapulmonary Pulmonary
Markers of disease impairment Airflow and volumes
Nutrition* FEV1 (post-bronchodilator)*
Body mass index Rate of decline
Fat-free mass index FVC
Skeletal (limb) muscle* FEV1/FVC ratio
Wasting Inspiratory capacity
Strength Bronchodilator reversibility
Systemic inflammation* Lung volumes*
Markers in blood, e.g. CRF, soluble TNFa Corticosteroid responsiveness
Blood gas tension* Bronchial hyperreactivity
Exercise* DLCO*
Self-reported Respiratory muscle function*
Timed walking test Pi max
Maximum exercise capacity Pe max
Disability (including handicap)* Pdi max
HRQOL (health status)* Variability in baseline lung function
High-resolution computerized tomography*
Predictors of disease severity Dyspnea*
Age (covariate for disease progression) Cough
Smoking status Frequency
Sleep disturbance/quality Intensity
Family history (a1-antitrypsin) Timing
Co-morbidity (number of organs/severity) Sputum production*
Atopy Frequency
Volume
Exacerbations
Structure (endobronchial biopsy)*
Inflammatory markers in biopsy, induced sputum and
bronchoalveolar lavage
Note: The 15 variables that could adequately represent information expressed by one or more of the others in the list are
indicated with an asterisk.
Abbreviations: CRF, C-reactive protein; DLCO, carbon monoxide pulmonary diffusing capacity; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; Pdi max, maximal diaphragmatic pressure; Pe max, maximal expiratory pressure; Pi max, maximal
inspiratory pressure; HRQOL, health-related quality of life; TNF, tumor necrosis factor.
B.R. Celli et al.1548variable, COPD and its outcome. However, inclusion
in this list did not require evidence that the
magnitude of the outcome, e.g. the risk of mortality,
was linearly related to the degree of abnormality of
the variable, nor that this variable was sensitive to
change with time and/or disease progression.
The variables in this list were then reassessed to
identify which of them could adequately represent
information expressed by one or more of the
others. This process reduced the number of
potential variables to 15 (indicated by an asterisk
in Table 1). To assess how practical it would be to
include these measurements in a staging system,
they were reviewed to determine whether their
properties were: discriminative (able to distinguish between dif-
ferent degrees of disease severity across pa-
tients); evaluative (able to respond to changes over time
and with therapy); reproducible between and within patients;
 independent of other candidate staging vari-
ables; and measurable, i.e. easy to use in any setting.
It was accepted that measures of inflammation
and pulmonary structure based on biopsy techni-
ques are currently neither sufficiently reproducible
between centers nor sufficiently well related to
other outcomes to be included in the system.
Likewise, the assessment of ventilatory pump
function using maximum pressure generation,
although more widely available than biopsy tech-
niques, still has problems with inter-laboratory
standardization. Measurement of dynamic lung
volumes during exercise helps to explain the
mechanisms of symptom production, but has not
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patient’s disability. Similar problems affect static
lung volumes, where the FEV1 value explains most
of the variability in the data; this variability is not
improved by including lung volume measurement.
Following this, six variables or groups of variables
remained: Nutritional status and peripheral muscle
strength—these correlate with survival and with
use of health care resources.8,16 Dyspnea, exercise capacity/self-paced walking
distance, health status and disability; these have
been shown to correlate with each other.18 Arterial blood gas tensions, which predict mor-
tality.11,19 Carbon monoxide diffusing capacity (DLCO) and
high-resolution computerized tomography
(HRCT) as measures of structural change. Sputum production as a marker of intra-pulmon-
ary inflammation.Table 2 Modified Medical Research Council scale
for dyspnea used in the patient database.
Grade Description
0 Not troubled with breathlessness
except with strenuous exercise
1 Troubled by shortness of breath
when hurrying on the level or
walking up a slight hill
2 Walks slower than people of the
same age on the level because of
breathlessness, or has to stop for
breath when walking at own pace on
the level
3 Stops for breath after walking about
100 yards or after a few minutes on
the level
4 Too breathless to leave the house, or
breathless when dressing or
undressingFEV1 as a defining characteristic and prognostic
marker.
The final test for suitability and inclusion in the
staging system was that the measurements could be
expressed as a single value and be assessed in a
simple and reliable fashion. Although peripheral
muscle strength can be assessed reproducibly in
research laboratories, this technique is not widely
available. The simplest and most reproducible
marker of nutritional status is the BMI (weight
[kg]/height [m2]) which is indirectly related to
peripheral muscle strength.
When the grouping of dyspnea, exercise capa-
city/walking distance, health status and disability
was considered, there were concerns that walking
tests would be difficult to standardize between
centers. Progressive exercise testing is relatively
complex and no single variable can be used to
express the outcome of these tests. Although self-
paced walking tests can be run in most rehabilita-
tion centers, they may exhibit ceiling effects, and
are most sensitive in individuals whose FEV1 is
o50% predicted and those with significant breath-
lessness on exertion. Exercise capacity measured in
this way is a determinant of health status20 and
may be of value in studying populations from a
single institution, where its measurement can be
carefully standardized. However, its inclusion
would restrict this staging system to patients
identified in the secondary care/hospital setting.
In contrast, the Medical Research Council (MRC)
dyspnea scale for the measurement of the impact
of breathlessness on a patient’s life is validated and
correlates with walking distance, health status andmortality.17,21,22 Several different versions of this
scale have been used; the version employed in this
report, the five-point modified MRC (MMRC) scale,
is presented in Table 2. It will be noted that Table 2
shows two scales, from 0–4 and 1–5; both are
commonly used. The proposed scheme is based on
the 0–4 scale, but it will be important to check
which scale is used when dyspnea measurements
from different research groups are compared, to
avoid possible errors.
Measurement of arterial blood gas tension is
predictive of mortality, reproducible and has been
standardized between centers. Blood gases mea-
surements can be considered when other non-
invasive measurements indicate that PaO2 may be
low, e.g. a pulse oxygen saturation of o92%.23
However, as significant arterial hypoxemia
(o60mmHg) is more likely when the FEV1 is
o35% predicted, blood gas measurement wads felt
to be an appropriate secondary staging category in
patients where the FEV1 falls to this level.
DLCO and HRCT both assess the severity of
pulmonary emphysema and are interrelated.
Although they are markers of structural damage in
COPD, it is not yet clear if they define a discrete
natural history, and this makes their routine
measurement more questionable. In the case of
HRCT, there is no universally agreed system of
standardizing images acquired from different
scanning protocols. If these issues can be ad-
dressed, the measurements may well be of value
in future modifications of this staging system, but
they were not included in the present one. Similar
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the independent contribution to the natural history
of the disease prevented the inclusion of sputum
measurements.
The FEV1 (and FEV1/FVC ratio) is central to the
accurate diagnosis of COPD, is reproducible in an
individual (with a known variability over time) and
is an indicator of when to measure blood gas
tensions. It remains a useful marker of the impact
of the different pathologies contributing to COPD
and it has been extensively validated in other
clinical studies.
In summary, the following three variables
were suggested for the staging system: FEV1
(with arterial blood gas tensions when this value
is below 40% predicted), MMRC dyspnea scale
and BMI.Threshold values
The selection of threshold values to indicate the
boundaries between one stage and another was
based on existing practice, in the case of the
spirometric variables as recommended by the
American Thoracic Society.24 In the case of MRC
breathlessness questionnaire, the threshold was
based on the structure of the instrument itself.
For BMI, the choice of 21 kg/m2 was based on
data relating mortality to initial BMI.11 The pro-
posed threshold for each variable is summarized in
Table 3.Table 3 Proposed threshold levels and scores of
FEV1, MMRC dyspnea scale and BMI for staging
COPD.
FEV1 (% predicted) MMRC
dyspnea scale
BMI (kg/m2)
X50% (1) 0 X21 (0)
30–49% (2) 1 o21 (1)
o30% (3) 2
For FEV1 o40% predicted measure arterial PaO2
X60mmHg (a) 3
o60mmHg (b) 4
Note: PaCO2 might be important (and may be related to
mechanical load applied) but was omitted for simplicity,
particularly as interpretation is problematic in patients
who receive oxygen.
Abbreviations: BMI, body mass index; FEV1, forced
expiratory volume in 1 s; MMRC, Modified Medical Re-
search Council. PaCO2 or PaO2, partial pressures of
arterial CO2 or O2.Validation of the properties of the staging
system
To confirm that the variables selected in the first
step of the process would identify different aspects
of the impact of COPD, a principal components
analysis (PCA) was performed (see below under
statistical methods) using a large database of COPD
patients in whom the relevant variables were
measured in a standardized fashion. PCA requires
a large ratio of subjects to variables to establish
that the individual factors are not related. The
database we used met this criterion, comprising
813 patients with COPD (diagnosed by a physician)
who participated in two clinical trials that com-
pared an active drug with placebo.25,26 The demo-
graphics and clinical characteristics of this
population are shown in Table 4.
Thirty original variables were analyzed: FEV1 forced vital capacity (FVC), forced expira-
tory flow rate between 25% and 75% (FEF2575 of
FVC), morning and evening peak expiratory flow
(PEF), and reversibility to salbutamol (Ventolins)
and ipratropium bromide (Atrovents); daytime
and nighttime symptoms (cough, chest discom-
fort and shortness of breath), nighttime awaken-
ings and on-demand salbutamol use (both during
day and night), from diary card data; six minute walk distance;27Table 4 Demographics and clinical characteris-
tics of patients in the study database.
Number of patients 813
Number of males/females (%) 31/69
Age (years) 6378.9
Smoking status (pack years) 61.7733
Current/former smokers (%) 42.1/57.9
Baseline FEV1 (liters) 1.2470.5
Baseline FEV1 (% predicted) 40.9712.4
Post-bronchodilator reversibility (% of patients)
Albuterol 28
Ipratropium 11
Both 34
Neither 27
Disease (% of patients)
Chronic bronchitis 26
Emphysema 47
Both 27
Note: Values are mean7SD.
Reversibility defined as a post-bronchodilator increase
in FEV1 of X200mL and X12% more than the baseline
assessment.
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six selected components derived from a principal
components analysis of respiratory variables in
patients with COPD.
Component Variable LoadingMMRC dyspnea scale, Baseline Dyspnea Index
(BDI),28 Borg category scale score (pre- and post-
6-min walk), Pittsburgh Sleep Quality Index
(PSQI) and Chronic Respiratory Disease Question-
naire (CRDQ) global and individual (dyspnea,
emotional function, fatigue and mastery) scores; 1 FEV1 0.87
FEF 0.63
FVC 0.81
Peak flow readings
(morning)
0.84
Peak flow readings
(evening)
0.84
Height 0.64
2 Cough (daytime) 0.71
Chest discomfort
(daytime)
0.70
Shortness of breath
(daytime)
0.53
Cough (nighttime) 0.80
Chest discomfort
(nighttime)
0.78
Shortness of breath
(nighttime)
0.77
Nighttime awakenings 0.69
On-demand salbutamol
(Ventolins) (nighttime)
0.50
Pre-Borg score 0.16
3 PSQI—global score 0.50
CRDQ: global score 0.95
CRDQ: dyspnea score 0.52
CRDQ: emotional
function score
0.84
CRDQ: fatigue score 0.80
CRDQ: mastery score 0.78
4 Ipratropium bromide
(Atrovents) FEV1
0.99height, weight and BMI.
PCA was applied to these 30 variables and
involved taking linear combinations of the original
variables to form 30 new independent variables
called indices (the
’ ’
components’’ of the analysis).
By observing the correlations between the indices
and the original variables, associations between
the original variables can be investigated, so that
sets of associated variables can be identified.
Before the analysis, the original variables are
scaled so that the sum of the variances of the
indices is equal to the number of variables, i.e. 30.
These variances correspond to the eigenvalues of
the correlation matrix of the original variables.29
The eigenvalue of each index is a measure of its
variability; those indices with negligible variability
contribute little to understanding the structure of
the original variables, i.e. the associations between
them. Conventionally, an eigenvalue of o1 is not
subjected to further analysis. The correlation of
the original variables with the principal compo-
nents is made clearer by varimax rotation. Each
correlation is called a loading and indicates how
strongly the original variable is associated with
each component (or how much the variable
’ ’
loads’’ on it). By observing which variables load
onto which components, it is possible to determine
the strength of the associations between the
original variables.29reversibility
Salbutamol (Ventolins)
FEV1 reversibility
0.99
5 Weight 0.81
Body mass index 0.94
Distance walked 0.42
6 MMRC dyspnea scale 0.46
BDI value 0.45
On-demand salbutamol
(Ventolins) (daytime)
0.60
Post-Borg score 0.36
Note: Loadings were calculated after varimax rotation.
The component loaded on to is that with which the
variable is correlated the most.
Abbreviations: BDI, Baseline Dyspnea Index; CRDQ,
Chronic Respiratory Disease Questionnaire; FEF, forced
expiratory flow; FEV1, forced expiratory volume in 1 s;
FVC, forced vital capacity; MMRC, Modified
Medical Research Council; PSQI, Pittsburgh Sleep Quality
Index.Results
When PCA was applied to the patient database,
eight components had eigenvalues greater than 1.
No original variable, however, loaded onto compo-
nent 7 and the loadings on component 8 were
weaker than those on the other components. These
two components were therefore removed from the
analysis, and the relationship between the original
30 variables and the remaining six components was
examined. The components with which each vari-
able was most strongly correlated after varimax
rotation are shown in Table 5, together with the
corresponding loadings.
The weakest loading by any variable was the pre-
6-min walk Borg category scale for breathlessness.
All other variables were moderately or closely
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six groups of variables were: (1) pulmonary func-
tion (including FEV1); (2) symptoms (including
cough and shortness of breath); (3) health status;
(4) bronchodilator reversibility; (5) BMI; and (6)
dyspnea (MMRC scale).
The analysis shows that these groups identify
independent categories of information about each
patient. The three principal measurements pro-
posed for the COPD staging system (FEV1, BMI and
MMRC dyspnea scale) appeared in different groups,
represented by loadings onto components 1, 5 and
6, respectively.Discussion
The American Thoracic Society has suggested that
the management of COPD would be greatly facili-
tated by a staging system that allows standardized
categorization of the heterogeneous population of
patients with this disorder.3 The staging system we
have devised represents an attempt to produce
such a picture of COPD. The development of this
system has been presented in detail to demonstrate
that the variables selected have not been chosen
randomly or by selective review of current data.
The choice of our initial candidate variables was
determined simply by demonstrating that there was
some evidence for an association between the
variable and the disease. Although we did not
conduct a standardized literature review, the
composition of the expert group assured a broad
range of expertise. We propose the existing system
as a beginning, expecting to revise it with other
variables provided the new variables meet our
other criteria of having proven discriminative and
evaluative properties and being simple and reliable
to use. Indeed, the three variables selected by this
process are identical to those that constitute the
recently validated BODE index.17
In applying these criteria, we had to discard
many mechanistically interesting and important
measurements; we would hope that improvements
in standardization of these markers, as well as
greater information about their relationship with
structural change and pulmonary inflammation will
eventually allow their inclusion in their revised
system. This will inevitably take some time, as the
process of relating outcome variables such as these
to the natural history of COPD and the impact of
the disease on individuals is slow. One reason for
the popularity of FEV1 as a staging marker is the
large amount of available data against which it can
be measured. The rate of decline of FEV1 as amarker for disease progression in the COPD popula-
tion has been confirmed repeatedly for the last 30
years;30 very recently, however, the rate of decline
of health status has been shown to be measurable
and to have different characteristics for the change
in FEV1.
31,32 Nevertheless, existing health status
measurement instruments were primarily devel-
oped as research tools and the need for the staging
system to employ simple numbers limits the
inclusion of such measurements. They do have the
advantage of incorporating a wide range of end
points not normally encompassed by the FEV1 alone
and as such have provided some of the rationale for
developing a system of this kind.
As noted previously, the selection of thresholds
for the staging is somewhat arbitrary and reflects
the shortage of generalizable information. The
threshold FEV1 value of 50% predicted is the initial
cut point in the American Thoracic Society defini-
tion and corresponds to the boundary between
GOLD stage II and stage III and reflects a point at
which mortality rates begin to diverge and the risks
for an individual patient rise. The choice of a 30%
threshold corresponds to the GOLD stage III, V
boundary. Since hypoxemia is increasingly common
in patients with an FEV1 of o40%, this was
suggested as the threshold to measure blood gases.
The only way to resolve these uncertainties is to
study large groups of patients longitudinally, to
determine how different threshold values relate to
important outcomes such as mortality and exacer-
bation frequency. Similar concerns apply to the
threshold for breathlessness on the MMRC scale,
and the selection of patients with a low BMI. The
latter variable is not related to mortality by a J-
curve, as might be expected, but instead greater
BMI appears to be relatively protective.16 There is,
however, a historical precedent for setting thresh-
old in this way. The original tumor/node/metastasis
(TNM) staging system for assessing the extent of
bronchial carcinoma spread was based on knowl-
edge of the biological basis of the disease, but not
on systematic studies examining the particular
thresholds. Such studies followed the establish-
ment of the classification and have led to some
modification, particularly of the threshold size for
lymph nodes. The systems should be seen to be
applicable to a wide range of patients and to offer
valuable information.
The relative independence of the staging vari-
ables was tested in a large but selected population
whose patients met the entry criteria for a clinical
study. That the PCA indicates six variables could
explain most of the variables in the rest supports
the concept that a multidimensional staging system
is appropriate for COPD. That the three variables
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independent main components supports the feasi-
bility of such an approach. The patients evaluated
in the PCA appear to be typical hospital out-
patients: two-thirds were male, the mean age was
63, the smoking history showed a mean of 60 pack
years and the mean baseline FEV1 was 1.4 L. The
variables selected as independent in this system
are generally similar to those reported in the other
three COPD populations where the PCA approach
has been adopted.33–35 These reports were not
available to the panel at the time when our system
was constructed, but provide reassurance that our
system is robust. Differences between these studies
and ours in respect of the weightings selected for
the PCA are likely to reflect differences in the input
variables, and again point to the need for prospec-
tive evaluation of this staging approach. Although
the analysis of our patient database showed that
bronchodilator reversibility is an independent
variable, we decided not to include it in the
staging system because of uncertainty about the
best way to express this measurement in COPD
patients; there is also evidence that it does not add
any more information than is provided by the post-
bronchodilator FEV1 when patients are followed
until death.36
As this analysis was being developed and sub-
mitted, an independently generated multidimen-
sional index based on the exploration of an initial
cohort of 207 patients and a validating one of 625
produced a very similar multidimensional index
composed of the following variables: BMI, the FEV1,
the MMRC dyspnea with the addition of the 6min
walk distance as a fourth variable.17 This BODE
index proved to be a better predictor of mortality
than the FEV1 measured in the same cohort. Using a
different method and a different population of
patients, that study validates the findings here
reported. Indeed, the PCA analysis included in this
report confirms that three of the components of the
BODE index: the FEV1, the BMI and the MMRC
dyspnea aggregate separate from each other, with
only the 6min walking differing in both reports.
Interestingly, the panel had selected the exercise
capacity as one possible variable capable of
providing independent information (Table 1). How-
ever, the group felt that it would be difficult to
standardize that test. Further, the PCA methodol-
ogy aggregated the 6-min walk distance with BMI
and since the latter was simple to obtain, it was not
included in the final analysis. It is important to note
that the database on which the PCA was conducted
was composed of patients enrolled in two identical
clinical trials and therefore represent a narrower
sample of patients with COPD than those includedin the BODE report. It is entirely possible that in the
BODE cohort with a much wider range of COPD
severity, the exercise performance could have a
wider range of values and hence proved to be a
more important and independent predictor of
outcome.
In closing, we would like to state that the
proposed system is applicable to many patients as
it is simple to obtain. However, the applicability to
populations different from the one here reported
remains to be determined.
The relatively simple but robust variables we
have selected can be retained as individual ways of
assessing the patient, or combined to provide a new
staging system. Until further data are available, we
propose that a patient’s illness is described using
the three staging variables of dyspnea, nutritional
state and degree of airflow limitation with the
threshold values we have described above. This
method of assessment should, we believe, be a
more comprehensive way of evaluating the COPD
patients than reliance on the last of these variables
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